🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment and prevention of Influenza.

    Lacuna Pharma Pty Ltd

    influenza

    phase 1 other active

    1 trial

  2. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of schizophrenia in adult patients.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects).

    phase 1 other active

    1 trial

  3. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of schizophrenia in adults patients.

    Lacuna Pharma Pty Ltd

    Bioequivalence study under fasting conditions

    phase 1 other active

    1 trial

  4. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of type 2 diabetes mellitus in adults and children aged 10 years and above, and heart failure and chronic kidney disease in adults patiens.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects.

    phase 1 other active

    1 trial

  5. This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adult participants with Chronic Inducible Urticaria (CIndU) to assess if it is safe and improves reactions to known CIndU triggers.

    Lacuna Pharma Pty Ltd

    Chronic Inducible Urticaria

    phase 1 other active

    1 trial

  6. To evaluate the pharmacokinetics and safety of nolasiban

    Novo Nordisk A/S

    not applicable (submitted trial is a pharmacokinetic study in healthy subjects)

    phase 1 other active

    1 trial

  7. Topiramate 2 x 25 mg tablet

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    1 trial

  8. Topiramate 25 mg Capsules

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    1 trial

  9. Topiramate Capsules, 25 mg

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  10. Topiramate IR

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy

    phase 1 small molecule completed

    1 trial

  11. Topiramate Tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    1 trial

  12. Trandolapril 4 mg Tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  13. Treatment A

    Tonix Pharmaceuticals Holding

    Healthy Adults

    phase 1 small molecule completed

    1 trial

  14. Treatment A

    Tonix Pharmaceuticals Holding

    Healthy

    phase 1 small molecule completed

    1 trial

  15. Treatment A (rosuvastatin)

    LEXICON PHARMACEUTICALS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  16. Treatment A digoxin

    LEXICON PHARMACEUTICALS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  17. Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  18. Treatment A: Fp MDPI

    Teva Pharma GmbH

    Asthma

    phase 1 small molecule completed

    1 trial

  19. Treatment of Respiratory Complications Associated with COVID-19, Influenza A, Metapneumovirus, Respiratory Syncytial Virus (RSV) Infection Using Wharton’s Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®): open Phase IB Clinical Trial

    Lacuna Pharma Pty Ltd

    Respiratory viral disease, COVID-19, Influenza A, Metapneumovirus, Respiratory syncytial virus Infection

    phase 1 other active

    1 trial

  20. Treatment sequence AB

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial

  21. Trial of the novel peroral anti-tumor treatment in patients with solid tumors

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma

    phase 1 other active

    1 trial

  22. Trial to evaluate the administration of IDOR-1134-2831 vaccine in healthy participants

    Lacuna Pharma Pty Ltd

    Clostridioides difficile (C. difficile)

    phase 1 other active

    1 trial

  23. Trichostatin A

    Vanda Pharmaceuticals Netherlands B.V.

    Relapsed or Refractory Hematologic Malignancies

    phase 1 small molecule active

    1 trial

  24. Tuberculosis Vaccine

    Biotech Pharmaceutical Co.,

    Tuberculosis

    phase 1 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources